Damora Therapeutics, Inc. (GLTO) is a publicly traded company in the Healthcare — Medical - Pharmaceuticals industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $21.58, GLTO has negative trailing earnings (P/E not meaningful) and an ROE of -82.56%. Market capitalisation stands at $34M.
Balance sheet quality for GLTO: current ratio of 13.0, net cash position of $257.6M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $21.58 |
| Market Cap | $34M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.68 |
| EV / EBITDA | 1.90 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -82.56% |
| Return on Invested Capital | -52.44% |
| Return on Assets | -48.35% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 19.73 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| GLTO | Damora Therapeutics, Inc. | $34M | 0.68 | -82.6% | |
| RPRX | Royalty Pharma plc | $25.9B | 24.26 | 3.81 | 12.3% |
| CORT | Corcept Therapeutics Incorporated | $12.1B | 207.35 | 16.10 | 8.4% |
| 0I3Q.L | Corcept Therapeutics Incorporated | $11.7B | 217.89 | 16.92 | 8.4% |
| LQDA | Liquidia Corporation | $6.1B | 42.09 | 30.09 | |
| KNSA | Kiniksa Pharmaceuticals International, plc | $5.9B | 72.84 | 9.24 | 13.7% |
| 0HF9.L | Amicus Therapeutics, Inc. | $5.3B | 19.37 | -12.0% | |
| PBH | Prestige Consumer Healthcare Inc. | $2.2B | 13.34 | 1.19 | 9.2% |
Price Performance
| 1 month | +0.00% |
| 3 months | +0.00% |
| Year-to-date | +10.86% |
| 1 year | +795.09% |
| 3 years | +72.95% |
| 5 years | -74.68% |
52-Week Range
| 52-week High | $38.33 |
| 52-week Low | $2.01 |
| Avg Volume (90d) | 887K |
Related companies: ACXP · ADIL · APRE · APVO · BCDA · INAB · KPRX
Explore sector: Healthcare · Medical - Pharmaceuticals
More sections of GLTO: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks